<code id='16A869662E'></code><style id='16A869662E'></style>
    • <acronym id='16A869662E'></acronym>
      <center id='16A869662E'><center id='16A869662E'><tfoot id='16A869662E'></tfoot></center><abbr id='16A869662E'><dir id='16A869662E'><tfoot id='16A869662E'></tfoot><noframes id='16A869662E'>

    • <optgroup id='16A869662E'><strike id='16A869662E'><sup id='16A869662E'></sup></strike><code id='16A869662E'></code></optgroup>
        1. <b id='16A869662E'><label id='16A869662E'><select id='16A869662E'><dt id='16A869662E'><span id='16A869662E'></span></dt></select></label></b><u id='16A869662E'></u>
          <i id='16A869662E'><strike id='16A869662E'><tt id='16A869662E'><pre id='16A869662E'></pre></tt></strike></i>

          Home / entertainment / leisure time

          leisure time


          leisure time

          author:focus    Page View:631
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In